Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.

Howard I. Scher, Robert Dreicer, Connie Lee et al.|Journal of Clinical Oncology|2014

Cited by 1